Literature DB >> 12716700

Group B streptococcal conjugate vaccines.

C J Baker1, M S Edwards.   

Abstract

Linkage of bacterial capsular polysaccharides to proteins to create conjugate vaccines has had a dramatic impact on the health of children. Although unconjugated polysaccharides are poorly immunogenic in infants and some older children and adults, their covalent coupling with proteins stimulates T cell dependent antigenic recognition that profoundly enhances immunogenicity. In the decade since the introduction and widespread use of Haemophilus influenzae type b polysaccharide conjugate vaccines in the United States, invasive H influenzae infections have become a rarity in childhood. Similarly, the conjugation of polysaccharides of Streptococcus pneumoniae to a derivative of diphtheria toxoid and the addition of pneumococcal conjugate vaccine to infant immunisation schedules carries with it promise for a similar decline in the incidence of invasive pneumococcal disease in paediatric patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12716700      PMCID: PMC1719562          DOI: 10.1136/adc.88.5.375

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  22 in total

1.  Group B streptococcal disease: from trials and tribulations to triumph and trepidation.

Authors:  A Schuchat
Journal:  Clin Infect Dis       Date:  2001-08-10       Impact factor: 9.079

2.  Maternal immunization: the influence of liability issues on vaccine development.

Authors:  P R Paradiso
Journal:  Vaccine       Date:  2001-10-15       Impact factor: 3.641

3.  Invasive group B streptococcal disease in Maryland nursing home residents.

Authors:  K J Henning; E L Hall; D M Dwyer; L Billmann; A Schuchat; J A Johnson; L H Harrison
Journal:  J Infect Dis       Date:  2001-03-01       Impact factor: 5.226

4.  Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis.

Authors:  S J Schrag; S Zywicki; M M Farley; A L Reingold; L H Harrison; L B Lefkowitz; J L Hadler; R Danila; P R Cieslak; A Schuchat
Journal:  N Engl J Med       Date:  2000-01-06       Impact factor: 91.245

5.  Group B streptococcal disease in nonpregnant adults.

Authors:  M M Farley
Journal:  Clin Infect Dis       Date:  2001-07-20       Impact factor: 9.079

6.  Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.

Authors:  L C Paoletti; M A Rench; D L Kasper; D Molrine; D Ambrosino; C J Baker
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

7.  Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women.

Authors:  C J Baker; L C Paoletti; M A Rench; H K Guttormsen; V J Carey; M E Hickman; D L Kasper
Journal:  J Infect Dis       Date:  2000-09-08       Impact factor: 5.226

8.  Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study.

Authors:  F Y Lin; J B Philips; P H Azimi; L E Weisman; P Clark; G G Rhoads; J Regan; N F Concepcion; C E Frasch; J Troendle; R A Brenner; B M Gray; R Bhushan; G Fitzgerald; P Moyer; J D Clemens
Journal:  J Infect Dis       Date:  2001-08-31       Impact factor: 5.226

9.  Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective.

Authors:  D R Murdoch; L B Reller
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

10.  Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.

Authors:  C J Baker; L C Paoletti; M R Wessels; H K Guttormsen; M A Rench; M E Hickman; D L Kasper
Journal:  J Infect Dis       Date:  1999-01       Impact factor: 5.226

View more
  36 in total

1.  A rapid genotyping test for the simultaneous detection and subtyping of group B streptococci: the frequency of molecular subtypes of group B streptococci in Korea.

Authors:  H R Lee; S H Song; H B Kim; K U Park; J Song
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-23       Impact factor: 3.267

2.  Neonatal sepsis and neutrophil insufficiencies.

Authors:  John Nicholas Melvan; Gregory J Bagby; David A Welsh; Steve Nelson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2010-06       Impact factor: 5.311

3.  Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity.

Authors:  Ravin Seepersaud; Sean B Hanniffy; Peter Mayne; Phil Sizer; Richard Le Page; Jerry M Wells
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

Review 4.  Group B streptococcal toxic shock syndrome in an asplenic patient: case report and literature review.

Authors:  K D Sims; T D Barton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-03       Impact factor: 3.267

Review 5.  Streptococcus adherence and colonization.

Authors:  Angela H Nobbs; Richard J Lamont; Howard F Jenkinson
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

Review 6.  Recent advances in understanding the molecular basis of group B Streptococcus virulence.

Authors:  Heather C Maisey; Kelly S Doran; Victor Nizet
Journal:  Expert Rev Mol Med       Date:  2008-09-22       Impact factor: 5.600

Review 7.  Considerations in the pharmacologic treatment and prevention of neonatal sepsis.

Authors:  Chris Stockmann; Michael G Spigarelli; Sarah C Campbell; Jonathan E Constance; Joshua D Courter; Emily A Thorell; Jared Olson; Catherine M T Sherwin
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

8.  Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.

Authors:  Hsiao-Hui Yang; Lawrence C Madoff; Hilde-Kari Guttormsen; Yong-Dong Liu; Lawrence C Paoletti
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

Review 9.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

Review 10.  Group B Streptococcus vaccine: state of the art.

Authors:  Annalisa Nuccitelli; C Daniela Rinaudo; Domenico Maione
Journal:  Ther Adv Vaccines       Date:  2015-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.